Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
ConditionPoly Cystic Ovary Syndrome
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorOctober 6 University
About this trial
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM
Eligibility criteria
Qualifiers
None
Disqualifiers
Patients with history of diabetes mellitus (Type 1 or 2).
Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months
Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors
Eating disorders (anorexia, bulimia) or gastrointestinal disorders
Trial design
Treatments tested in this trial
- Metformin Hydrochloride tablet
- Vildagliptin 50 MG
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov